CoreWeave, Inc. - Class A Common Stock (CRWV)

Today, Nov. 13, 2026, CoreWeave's shares slid as investors weighed a possible equipment-backed loan against its rapid buildout.

Despite both generating triple-digit revenue growth, investors picked one winner.

Microsoft's latest move could completely change the outlook for some neocloud companies.

The AI cloud provider can't add capacity fast enough. Will the memory maker sell more chips because of it?

AI companies are on track to borrow so much money that it might nearly match the size of the overall $12 trillion U.S. corporate bond market.

CoreWeave's Q3 revenue grew nearly 170% and backlog topped $130 billion, easing debt concerns as analysts reaffirmed ratings despite lowering some price targets.

Wall Street may have been wrong about the company after all.

It's time to look a little bit off the beaten path at some of the names errantly dragged lower by the recent sell-off of several artificial intelligence stocks.

AI data centers were a big loser of the midterm elections.

New financing options could reduce the cost of the neocloud's expansion.

The tech-heavy index has been unusually volatile lately.

On Nov. 11, 2026, the specialized AI cloud provider's shares rallied as its revenue topped expectations and it lifted its full-year outlook.

CoreWeave's strong quarter took some of the AI debt worry off the table and gave Oracle stock a lift.

No matter how you feel about AI stocks, there is room for optimism about the future of the stock market.

Record demand and a plan to avoid pricey bond debt eased investors’ fears, but CoreWeave still has to prove its profits can outgrow its interest bill.

CoreWeave's explosive growth in AI creates significant potential, but its financial obligations are equally substantial. Discover what could determine whether this infrastructure expansion rewards investors.

AI infrastructure is being funded with debt and stock sales while biotech companies applying AI are booking revenue, led by Tempus AI, Recursion and iShares Biotechnology

Alphabet and CoreWeave are both positioned to benefit from AI, but one has a much stronger financial foundation.

CoreWeave plunged over the last month, but the company is in a stronger position than investors think.

Once initial contracts end, CoreWeave owns the hardware outright, so renewals carry no new capital spending, a dynamic that shapes long-term margin potential.

Revenue jumped 168% as operating income beat management's own guidance range.